Novartis ESMO Event Presentation

Prostate cancer is the second most common cancer in men worldwide 1.4 million Prostate cancer cases worldwide per year 30% 5-year survival prognosis for mCRPC patients +4 months median OS benefit from current SoC seen in VISION study SoC heavily reliant on hormonal therapies (castration) >375k Prostate cancer deaths per year WW Source: Wang L. Et all, Front. Public Health, 16 February 2022 (Frontiers | Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019 (frontiersin.org)) 5 NOVARTIS ESMO EVENT | OCTOBER 24, 2023 | INVESTOR PRESENTATION NOVARTIS | Reimagining Medicine

View entire presentation